Key facts
- It has raised $15.4M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Hefei Hi-Tech VC, Anhui Investment Group Holdings, Anhui Lianyuan Venture Capital, Anhui Guokong Capital, Anhui Provincial Emerging Industry Investment — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Tarapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tarapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tarapeutics
Developer of therapeutic drug candidates based on advanced delivery technologies intended to treat cancer and other chronic diseases. The company offers a research and development pipeline that includes targeted drug candidates, platform technologies for precision delivery at the cellular and molecular level, and preclinical development capabilities focused on oncology and chronic illness, enabling pharmaceutical partners, clinical researchers, and healthcare stakeholders to address unintended systemic effects.
- Sector
- Healthcare
- HQ
- Bangbu, China
- Founded
- 2019
- Employees
- 4
- Website
- tarapeutics.com/
- Ownership
- Privately Held (backing)
Tarapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tarapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tarapeutics in its N-PORT filings yet. We sweep new filings monthly.